Small risk of severe acute pancreatitis with weight-loss jabs, UK regulator warns
Agency updates guidance after increase in reports of condition to its yellow card scheme
Patients on weight-loss jabs and diabetes injections should be aware there is a small risk of developing severe acute pancreatitis, the UK medicines regulator has said.
About 1.6 million adults in England, Wales and Scotland used GLP-1 medication, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), between early 2024 and early 2025 to lose weight, according to recent research.